Parallel synthesis and biological activity of a new class of high affinity and selective δ-opioid ligand

被引:18
作者
Barn, DR
Caulfield, WL
Cottney, J
McGurk, K
Morphy, JR [1 ]
Rankovic, Z
Roberts, B
机构
[1] Organon Labs Ltd, Newhouse ML1 5SH, Scotland
[2] NV Organon, NL-5430 BH Oss, Netherlands
[3] AstraZeneca, Macclesfield SK10 4TG, Cheshire, England
关键词
D O I
10.1016/S0968-0896(01)00017-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A considerable number of research papers describing the synthesis and testing of the delta opioid receptor (DOR) ligands, SNC-80 and TAN-67, and analogues of these two compounds, have been published in recent years. However, there have been few reports of the discovery of completely new structural classes of selective DOR ligand. By optimising a hit compound identified by high throughput screening, a new series of tetrahydroisoquinoline sulphonamide-based delta opioid ligands was discovered. The main challenge in this series was to simultaneously improve both affinity and physico chemical properties, notably aqueous solubility. The most active ligand had an affinity (IC50) of 6 nM for the cloned human DOR, representing a 15-fold improvement relative to the original hit I (IC50 98 nM). Compounds from this new series show good selectivity for the DOR over mu and K opioid receptors. However the most active and selective compounds had poor aqueous solubility. Improved aqueous solubility was obtained by replacing the phthalimide group in I by basic groups, allowing the synthesis of salt forms. A series of compounds with improved affinity and solubility relative to I was identified and these compounds showed activity in an in vivo model of antinociception, the formalin paw test, In the case of compound 19, this analgesic activity was shown to be mediated primarily via a DOR mechanism. The most active compound in vivo, 46, showed superior potency in this test compared to the reference DOR ligand, TAN-67 and similar potency to morphine (68% and 58% inhibition in Phases 1 and 2, respectively, at a dose of 10 mmol/kg i.v.). (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:2609 / 2624
页数:16
相关论文
共 16 条
[11]   DESIGN OF PEPTIDOMIMETIC DELTA-OPIOID RECEPTOR ANTAGONISTS USING THE MESSAGE ADDRESS CONCEPT [J].
PORTOGHESE, PS ;
SULTANA, M ;
TAKEMORI, AE .
JOURNAL OF MEDICINAL CHEMISTRY, 1990, 33 (06) :1714-1720
[12]   DEVELOPMENT OF DELTA OPIOID-PEPTIDES AS NONADDICTING ANALGESICS [J].
RAPAKA, RS ;
PORRECA, F .
PHARMACEUTICAL RESEARCH, 1991, 8 (01) :1-8
[13]   A NOVEL OPIOID STRUCTURE WHICH ACCEPTS PROTONATED AS WELL AS NON-PROTONATED NITROGEN - A FAMILY OF PURE, DELTA RECEPTOR SELECTIVE ANTAGONISTS [J].
RONAI, AZ ;
BOTYANSZKI, J ;
HEPP, J ;
MEDZIHRADSZKY, K .
LIFE SCIENCES, 1992, 50 (18) :1371-1378
[14]   Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity [J].
Salvadori, S ;
Balboni, G ;
Guerrini, R ;
Tomatis, R ;
Bianchi, C ;
Bryant, SD ;
Cooper, PS ;
Lazarus, LH .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (19) :3100-3108
[15]   Novel ligands lacking a positive charge for the δ- and μ-opioid receptors [J].
Schiller, PW ;
Berezowska, I ;
Nguyen, TMD ;
Schmidt, R ;
Lemieux, C ;
Chung, NN ;
Falcone-Hindley, ML ;
Yao, WQ ;
Liu, J ;
Iwama, S ;
Smith, AB ;
Hirschmann, R .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (04) :551-559
[16]   EFFECTS OF A HIGHLY SELECTIVE NONPEPTIDE DELTA-OPIOID RECEPTOR AGONIST, TAN-67, ON MORPHINE-INDUCED ANTINOCICEPTION IN MICE [J].
SUZUKI, T ;
MINORU, T ;
MORI, T ;
MISAWA, M ;
ENDOH, T ;
NAGASE, H .
LIFE SCIENCES, 1995, 57 (02) :155-168